200 Employees at Kulmbach Site

April 2023

We are very pleased to welcome our 200th employee at the Kulmbach site!

Our strong growth reflects the strength of the Axolabs team and extends our expertise to further support your therapeutic nucleic acid projects.

200 Axolabs employee

Axolabs Kulmbach Now Certified  Provider

January 2023

At Axolabs Kulmbach we are happy to announce that we are now an officially certified Service Provider of Oxford Nanopore Technologies long-read sequencing technique.

Quite recently Nature Methods has choosen the long-read sequencing technique as their "Method of the year". 

Learn more: Nature Methods


Axolabs is evolving!

November 2022

Our three locations (Berlin & Kulmbach, Germany & Petaluma, US) support customers across all stages of oligonucleotide development by harnessing the expertise of more than 20 years of experience in Nucleic Acid Therapeutics.

Our updated logo reflects a common vision for all locations; we aim to be the world leading and trusted service partner for delivering custom research and manufacturing.

Axolabs Logo

Management Changes

March 2022

On March 31, 2022, Hans-Peter Vornlocher stepped down from the day-to-day management of Axolabs taking the first step towards a well-earned retirement. His successor will be Philipp Hadwiger, Senior Director of Chemistry, an experienced colleague who has held leading positions at Axolabs (and its predecessor companies) for more than 20 years, and has played a key role in Axolabs’ growth and expansion. In anticipation of this change, Philipp has already been involved in the Axolabs’ extended management board in recent years.

Hans-Peter will continue to work part-time for Axolabs, advising our customers and driving the development of new technologies as Axolabs’ new Chief Scientific Officer (CSO). His enormous wealth of knowledge and experience will therefore still be available to our present and future customers.

With this structure, we can ensure a smooth management transition and continue to be a competent partner and service provider for our customers as we always have been, serving our customers individually and delivering projects with the highest quality.

Philipp will manage our rapidly and steadily growing company with his incumbent managing director colleagues, Dr. Ingo Röhl and Friedrich Sanders, all of whom report to LGC’s management board.

Axolabs Expands GLP-Compliant Test Site Capabilities

Kulmbach, 18 February 2022

Today Axolabs announced the third successful re-certification of its GLP bioanalytical testing facility. The German authorities formally certified Axolabs’ compliance with international Good Laboratory Practice (GLP), without any objections, as part of a recent audit of Axolabs' bioanalytical GLP facility. The authorities also certified Axolabs' GLP laboratories for the new testing category 1 (physical and chemical testing). 

This significantly expands Axolabs' ability to support its customers with test item analysis (e.g. Dose Formulation Analysis) during GLP toxicology studies.

Ingo Röhl, Managing Director at Axolabs, said, “The successful GLP certification of the new test category provides an additional platform for even stronger collaboration with our clients in their oligonucleotide and mRNA therapeutic development activities. 

Axolabs has been on a strong growth course since its foundation and is currently expanding its bioanalytical facilities and capabilities even further.

Statement of GLP Compliance

Axolabs to Establish New Site in Berlin for GMP Manufacturing of Nucleic Acid Therapeutics 

November 2021

  • Site will be dedicated to medium to large scale and early to late phase clinical GMP manufacturing of nucleic acid therapeutics
  • State-of-the-art facility will deliver integrated analytical and manufacturing solutions
  • Operational start date is scheduled for 2024

Axolabs Certified as GMP-Compliant Test Site

Kulmbach, 29 September 2021

Today Axolabs announced the achievement of a major milestone at its site in Kulmbach, Germany.  German authorities recently inspected Axolabs’ existing 400 m² GMP-CMC analytical facility and formally certified its compliance with international Good Manufacturing Practice (GMP) standards. Axolabs is now a certified test site for stability testing and the official release of human medicinal products and human investigational medicinal products, in particular therapeutics based on oligonucleotides and mRNAs, and including mRNA vaccines. This significantly expands Axolabs' capabilities in development solutions for therapeutic oligonucleotides and mRNAs. 

Ingo Röhl, Managing Director at Axolabs, said, “The successful GMP certification provides an additional platform for an even stronger collaboration with our clients in their oligonucleotide and mRNA therapeutics development activities.  We are glad we can add analytical services under GMP as a new dimension to our services in biology, synthetic chemistry and other analytical areas.”

The new capability in Germany complements LGC's established CMC analysis laboratories in the UK, as well as its cGMP manufacturing and oligonucleotide CMC laboratories in Petaluma, California.  LGC can now offer its customers a global platform to support their drug development and manufacturing programs.

Axolabs has been on a strong growth course since its foundation and is currently expanding its Kulmbach facilities in all business areas.

GMP Certificate

New GMP Analytical Capability

Kulmbach - London, 1 October, 2018

Today, LGC Axolabs announces a significant investment at its site at Kulmbach, Germany, to expand the capacity of its specialist therapeutic oligonucleotide development solutions business and create a new GMP analytical capability. 

Due to open in February 2019, the new 800m² labs comprise additional bioanalysis and synthetic chemistry labs as well as a new GMP CMC analytical capability for batch release testing of oligonucleotide-based drug substances and drug products in the EU.      

The new facility will complement LGC’s established bioanalytical and CMC analytical labs in the UK, as well as their oligonucleotide cGMP manufacture and CMC labs in Petaluma, California which is due to run its first cGMP manufacturing campaigns later this year.  LGC now offers its clients a truly global platform to support drug development and manufacturing.

Hans-Peter Vornlocher, Managing Director, Research at LGC Axolabs, said, “This investment provides a platform for growth of our oligonucleotide therapeutics development activities, expanding our total site capacity to around 4,500m2 and to around 100 scientists.  We are also glad to be able to add GMP analytical services as a new dimension to our biology, synthetic chemistry and other analytical services”.

David Griffiths, Managing Director, Pharma & Health Solutions, LGC, said, “We’re excited about this expansion which not only supports growth of our Kulmbach site but is also part of a larger international growth strategy for LGC’s drug development solutions business giving access and greater flexibility for our clients”. The investment in Kulmbach supplements LGC’s announcement last year of further investment at its Petaluma site as well as the recent completion of the first phase in a long-term major investment to expand capacity of its bioanalytical labs in Fordham, UK.